Golimumab, a human monoclonal antibody specific to TNF-α, was tested over 52 weeks against a placebo in 84 children and young adults (ages 6 to 21) with newly diagnosed overt T1D. This evidence concerns the gene TNF and type 1 diabetes mellitus.